Pembrolizumab: as a tool

13 studies: an imaging tracer or a test of drug response. Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerNot yet recruitingNCT07892300Early Phase 1Report a problem
• Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without ImmunotherapyNot yet recruitingNCT06976021Phase 2Report a problem
• Drug Screening Using IMD in Bladder CancerEnrolling by invitationNCT06204614Early Phase 1Report a problem
• Drug Screening Using Novel IMD in Renal Cell CarcinomaRecruitingNCT05700461Phase 1Report a problem
• Drug Screening Using Novel IMD in Salivary and Head and Neck CancersRecruitingNCT05553782Early Phase 1Report a problem
• Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate CancerEnrolling by invitationNCT04399876Phase 1Report a problem
• Implantable Microdevice for TNBC - Pilot StudyWithdrawnNCT05774886Phase 1Report a problem
• 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body RadiationWithdrawnNCT05728372Early Phase 1Report a problem
• 64Cu-DOTA-pembrolizumab PET for the Study of PD1 ExpressionWithdrawnNCT04605614Phase 1Report a problem
• Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedNCT03432741Phase 1Report a problem
• 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung CancerStatus unknownNCT03065764Phase 2Report a problem
• Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue SarcomaCompletedNCT03056599Phase 1Report a problem
• Pembrolizumab-PET ImagingCompletedNCT02760225Not applicableReport a problem

← Pembrolizumab